BR112014002621A2 - anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento - Google Patents

anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento

Info

Publication number
BR112014002621A2
BR112014002621A2 BR112014002621A BR112014002621A BR112014002621A2 BR 112014002621 A2 BR112014002621 A2 BR 112014002621A2 BR 112014002621 A BR112014002621 A BR 112014002621A BR 112014002621 A BR112014002621 A BR 112014002621A BR 112014002621 A2 BR112014002621 A2 BR 112014002621A2
Authority
BR
Brazil
Prior art keywords
antibody
dna
treatment method
pharmaceutical
pharmaceutical composition
Prior art date
Application number
BR112014002621A
Other languages
English (en)
Other versions
BR112014002621B1 (pt
Inventor
Okano Fumiyoshi
Kobayashi Shinichi
Saito Takanori
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of BR112014002621A2 publication Critical patent/BR112014002621A2/pt
Publication of BR112014002621B1 publication Critical patent/BR112014002621B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
BR112014002621-1A 2011-08-04 2012-08-03 Anticorpo, ou seu fragmento, composição farmacêutica, uso de um anticorpo e uso de uma composição farmacêutica BR112014002621B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011-171332 2011-08-04
JP2011171332 2011-08-04
PCT/JP2012/069857 WO2013018892A1 (ja) 2011-08-04 2012-08-03 癌の治療及び／又は予防用医薬組成物

Publications (2)

Publication Number Publication Date
BR112014002621A2 true BR112014002621A2 (pt) 2017-12-12
BR112014002621B1 BR112014002621B1 (pt) 2022-09-20

Family

ID=47629406

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014002621-1A BR112014002621B1 (pt) 2011-08-04 2012-08-03 Anticorpo, ou seu fragmento, composição farmacêutica, uso de um anticorpo e uso de uma composição farmacêutica

Country Status (17)

Country Link
US (1) US9181334B2 (pt)
EP (1) EP2740793B1 (pt)
JP (1) JP6015448B2 (pt)
KR (1) KR101968498B1 (pt)
CN (1) CN103717738B (pt)
AU (1) AU2012290955B2 (pt)
BR (1) BR112014002621B1 (pt)
CA (1) CA2844038C (pt)
DK (1) DK2740793T3 (pt)
ES (1) ES2660115T3 (pt)
HU (1) HUE035689T2 (pt)
MX (1) MX348579B (pt)
PL (1) PL2740793T3 (pt)
PT (1) PT2740793T (pt)
RU (1) RU2624049C2 (pt)
TR (1) TR201802089T4 (pt)
WO (1) WO2013018892A1 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011001445A (es) 2008-08-05 2011-04-05 Toray Industries Metodo para detectar cancer.
CA2733223C (en) 2008-08-05 2018-02-27 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibody for treatment and prevention of cancers
MX340015B (es) * 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
WO2013018885A1 (ja) * 2011-08-04 2013-02-07 東レ株式会社 膵臓癌の検出方法
EP2740489B1 (en) * 2011-08-04 2016-10-05 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
IN2014KN01715A (pt) 2012-02-21 2015-10-23 Toray Industries
PL2832366T3 (pl) 2012-03-30 2018-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego
CA2869120C (en) * 2012-03-30 2023-05-23 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
RU2646466C2 (ru) 2012-07-19 2018-03-05 Торэй Индастриз, Инк. Метод детекции рака
JP6244912B2 (ja) 2012-07-19 2017-12-13 東レ株式会社 癌の検出方法
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
WO2014110601A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
EP3587448B1 (en) * 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
CA2918989C (en) 2013-08-09 2021-11-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
CR20160506A (es) 2014-03-28 2017-03-10 Xencor Inc Anticuerpos biespecíficos que se unen a cd38 y cd3
CA2968878A1 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
DK3223845T3 (da) 2014-11-26 2021-08-16 Xencor Inc Heterodimere antistoffer, der binder cd3 og cd20
CN108699136B (zh) 2015-12-07 2022-03-18 Xencor股份有限公司 结合cd3和psma的异二聚抗体
WO2017218707A2 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
KR20230149857A (ko) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
AU2017348734A1 (en) 2016-10-28 2019-05-16 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
BR112020019935A2 (pt) 2018-03-30 2021-01-26 Toray Industries, Inc. medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método de tratamento e/ou prevenção do câncer
EP3930850A1 (en) 2019-03-01 2022-01-05 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
WO2020252294A1 (en) 2019-06-13 2020-12-17 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
EP4038053A1 (en) 2019-09-30 2022-08-10 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
MX2022004875A (es) 2019-10-25 2022-06-17 Bolt Biotherapeutics Inc Inmunoconjugados de tienoazepina, inmunoconjugados y usos de estos.
WO2021182573A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び／又は予防のための医薬品
JPWO2021182570A1 (pt) 2020-03-12 2021-09-16
US20230165957A1 (en) 2020-03-12 2023-06-01 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4119160A4 (en) 2020-03-12 2024-04-03 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
JPWO2021182572A1 (pt) 2020-03-12 2021-09-16
US20230293716A1 (en) 2020-05-08 2023-09-21 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
EP4196168A1 (en) 2020-08-13 2023-06-21 Bolt Biotherapeutics, Inc. Pyrazoloazepine immunoconjugates, and uses thereof
AU2021329378A1 (en) 2020-08-19 2023-03-23 Xencor, Inc. Anti-CD28 compositions
CN117157319A (zh) 2021-03-09 2023-12-01 Xencor股份有限公司 结合cd3和cldn6的异二聚抗体
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
AU2022298240A1 (en) 2021-06-23 2024-01-18 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JPWO2022270523A1 (pt) 2021-06-23 2022-12-29
JPWO2023008461A1 (pt) 2021-07-27 2023-02-02
KR20240041917A (ko) 2021-07-27 2024-04-01 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
KR20240042416A (ko) 2021-07-27 2024-04-02 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
AU2022338463A1 (en) 2021-09-03 2024-03-21 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
CA3234604A1 (en) 2021-10-29 2023-05-04 Shelley Erin ACKERMAN Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
WO2001032910A2 (en) 1999-10-29 2001-05-10 Human Genome Sciences, Inc. 27 human secreted proteins
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
TW200532020A (en) 1998-07-14 2005-10-01 Corixa Corp Compositions and methods for therapy and diagnosis of prostate cancer
RU2234942C2 (ru) 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6335170B1 (en) 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
AU4185100A (en) 1999-04-02 2000-10-23 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
CA2404233A1 (en) 2000-03-29 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
AU2002311787A1 (en) 2001-03-28 2002-10-15 Zycos Inc. Translational profiling
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2002092001A2 (en) 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP2005535290A (ja) 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
US20050003390A1 (en) 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
WO2004047728A2 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
AU2004235382A1 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing AML and MDS differential gene expression
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
EP1711525A2 (en) * 2004-01-26 2006-10-18 Debiovision Inc. Neoplasm-specific polypeptides and their uses
MXPA06010715A (es) 2004-03-19 2007-05-23 Imclone Systems Inc Anticuerpo del receptor del factor de crecimiento humano anti-epidermico.
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
CN101141981A (zh) 2005-01-21 2008-03-12 健泰科生物技术公司 Her抗体的固定剂量给药
US7858324B2 (en) 2005-02-18 2010-12-28 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
NZ560976A (en) 2005-03-11 2011-06-30 Univ Johns Hopkins Biomarkers for ovarian cancer and endometrial cancer: hepcidin
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
EP1991701A4 (en) 2006-02-14 2010-03-17 Dana Farber Cancer Inst Inc COMPOSITIONS, KITS, AND METHODS FOR IDENTIFYING, EVALUATING, PREVENTING, AND TREATING CANCER
US20100015724A1 (en) 2006-08-17 2010-01-21 Peter Hornbeck Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7615349B2 (en) 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
PL2324842T3 (pl) 2008-08-05 2015-08-31 Toray Industries Środek indukujący odporność
CA2733223C (en) * 2008-08-05 2018-02-27 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibody for treatment and prevention of cancers
MX2011001445A (es) 2008-08-05 2011-04-05 Toray Industries Metodo para detectar cancer.
JP5734978B2 (ja) 2009-08-19 2015-06-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｆｆｐｅ材料におけるインテグリン複合体検出のための抗体
CA2773240C (en) 2009-09-22 2015-11-10 Volker Sandig Process for producing molecules containing specialized glycan structures
RU2418587C1 (ru) * 2010-01-21 2011-05-20 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") Способ лечения злокачественных опухолей головного мозга
RU2624029C2 (ru) 2010-02-04 2017-06-30 Торэй Индастриз, Инк. Лекарственный препарат для лечения и/или профилактики рака
KR101871704B1 (ko) 2010-02-04 2018-06-27 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
US8709418B2 (en) 2010-02-04 2014-04-29 Toray Industries, Inc. Pharmaceutical composition for treating CAPRIN-1 expressing cancer
PT2532365T (pt) 2010-02-04 2016-07-28 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro
HUE030742T2 (en) 2010-02-04 2017-06-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
MX340015B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
WO2013018885A1 (ja) 2011-08-04 2013-02-07 東レ株式会社 膵臓癌の検出方法
PT2740796T (pt) 2011-08-04 2017-07-26 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
EP2740489B1 (en) 2011-08-04 2016-10-05 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
CA2869120C (en) 2012-03-30 2023-05-23 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
PL2832366T3 (pl) 2012-03-30 2018-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego

Also Published As

Publication number Publication date
EP2740793A1 (en) 2014-06-11
DK2740793T3 (en) 2018-01-22
EP2740793B1 (en) 2017-11-29
US9181334B2 (en) 2015-11-10
HUE035689T2 (en) 2018-05-28
TR201802089T4 (tr) 2018-03-21
BR112014002621B1 (pt) 2022-09-20
CN103717738B (zh) 2015-07-15
RU2624049C2 (ru) 2017-06-30
PT2740793T (pt) 2018-02-23
JPWO2013018892A1 (ja) 2015-03-05
MX2014001373A (es) 2014-05-21
EP2740793A4 (en) 2015-04-01
AU2012290955B2 (en) 2017-04-27
CA2844038A1 (en) 2013-02-07
ES2660115T3 (es) 2018-03-20
US20140199311A1 (en) 2014-07-17
JP6015448B2 (ja) 2016-10-26
AU2012290955A1 (en) 2014-03-20
CA2844038C (en) 2019-05-07
MX348579B (es) 2017-06-20
CN103717738A (zh) 2014-04-09
KR101968498B1 (ko) 2019-04-12
PL2740793T3 (pl) 2018-04-30
RU2014108042A (ru) 2015-09-10
KR20140054186A (ko) 2014-05-08
WO2013018892A1 (ja) 2013-02-07

Similar Documents

Publication Publication Date Title
BR112014002621A2 (pt) anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento
BR112014021103A8 (pt) anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
BR112013023653A2 (pt) anticorpo biespecífico, método de preparação do anticorpo, e composição farmacêutica
BR112014023937A2 (pt) composição farmacêutica, agente farmacêutico de combinação e método de tratamento
BR112014025726A2 (pt) mecanismo, sistema e método para tratamento endodôntico
BR112013030520A2 (pt) método, sistema, e, composição.
PL2672966T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
BR112013033811A2 (pt) composição, método de preparação da composição, e, composto
PT2729151T (pt) Composição farmacêutica, métodos de tratamento e suas utilizações
BR112013021971A2 (pt) sistema médico e método.
BR112013010725A2 (pt) método, e, composição
BR112013008905A2 (pt) mecanismo de dosagem e método de dosagem
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
BR112013021984A2 (pt) métodos e sistema de tratamento de poço
BR112013032225A2 (pt) método para purificar toxina de difteria, e, formulação
BR112014004192A2 (pt) composição de tratamento de sementes, e, método de tratamento de sementes
BR112014010201A2 (pt) método, e sistema de levantamento
BR112013014644A2 (pt) composição farmacêutica e complexo
BR112013030381A2 (pt) reagentes e métodos para tratar doença dental
BR112014009889A2 (pt) compostos dissubstituídos, compostos e composição farmacêutica
BR112014007864A2 (pt) sistema, e método
BR112014015717A8 (pt) sistema, e método
BR112013022306A2 (pt) método, e, composição
BR112013022820A2 (pt) método de tratamento
BR112014031512A2 (pt) composição cosmética e método para o tratamento cosmético.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/08/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.